US › Healthcare

Prime Medicine, Inc. Common Stock (PRME)

US · Healthcare · Biotechnology

$2.98+6.05%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$856,000
Revenue YoY
-41.1%
Net profit
$-49.1M
Profit YoY
+5.3%
EPS
$-0.28
EPS estimate
$-0.25
Net margin
-5,738.6%

EPS came in at -0.28 against a street estimate of -0.25 — a miss of 12.0%.

Key statistics

Market cap
$507.5M
Forward P/E
0.0
P/B
6.88
Book value
$0.42
EPS (TTM)
$-1.23
52-week high
$6.94
52-week low
$2.67
50-day MA
$3.27
200-day MA
$3.72
Beta
2.31

Analyst view

Analysts rate Prime Medicine, Inc. Common Stock a buy (8 buy, 4 hold, 0 sell out of 12) with an average price target of $7.12.

Shareholding

Insiders
23.76%
Institutions
66.82%

Largest institutional holders

FundStake
Alphabet Inc9.17%
BlackRock Inc4.71%
Vanguard Group Inc3.58%
State Street Corp3.51%
ARK Investment Management LLC3.46%
T. Rowe Price Investment Management,Inc.3.04%
Vanguard Capital Management, LLC2.48%
Balyasny Asset Management LLC2.28%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Prime Medicine, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.